Soligenix, Inc. - Common Stock (SNGX)
4.9600
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 19th, 8:58 AM EDT
Detailed Quote
| Previous Close | 4.960 |
|---|---|
| Open | - |
| Bid | 3.870 |
| Ask | 3.880 |
| Day's Range | N/A - N/A |
| 52 Week Range | 1.090 - 6.230 |
| Volume | 676,834 |
| Market Cap | 17.38M |
| PE Ratio (TTM) | -1.337 |
| EPS (TTM) | -3.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 29,935,492 |
Chart
About Soligenix, Inc. - Common Stock (SNGX)
Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs. The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options. Read More
News & Press Releases
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · August 19, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 18, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · August 18, 2025
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · August 18, 2025
Discover the most active stocks in Monday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · August 18, 2025
Via Benzinga · August 18, 2025
Soligenix shares surge after FDA granted orphan drug designation to dusquetide for Behçet's Disease, boosting prospects for rare disease treatment.
Via Benzinga · August 18, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · August 18, 2025
Synergy CHC Corp. (NASDAQ: SNYR) is supercharging its retail expansion with a nationwide rollout of FOCUSfactor® Focus + Energy through EG America, the 6th largest U.S. convenience chain . The deal instantly places the functional brain health beverage in 1,600+ high-traffic locations , including Cumberland Farms, Turkey Hill, Tom Thumb (Albertsons Companies Inc. – NYSE: ACI), Loaf ’N Jug, and Minit Mart .
Via AB Newswire · August 18, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · August 18, 2025
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the U.S. FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treatment of Behçet’s Disease. The designation follows a review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients.
Via Investor Brand Network · August 18, 2025
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · August 18, 2025
Via Benzinga · August 18, 2025
Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure. Supported by proprietary stabilization technology and robust preclinical data demonstrating long-lasting immunity, SNGX’s RiVax represents both a critical public safety innovation and a significant market opportunity in the specialized vaccine sector.
Via Investor Brand Network · August 15, 2025
Study Finds That Low BSA Psoriasis Could Have a High Disease Burden
For decades, the severity of psoriasis has been classified on the basis of thresholds reflecting the BSA, or body surface area, impacted by the condition. Under this classification, individuals with less than 3 percent of BSA were categorized as having mild psoriasis; those with a BSA ranging between 3 and 10 percent were regarded as having moderate psoriasis; while those with a BSA in excess of 10 percent were classified as having severe psoriasis.
Via Investor Brand Network · August 15, 2025
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline
Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL is actively enrolling, with results anticipated in 2026. Soligenix also completed a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease, achieving its primary objective of demonstrating biological efficacy, and transferred manufacturing of synthetic hypericin to the U.S. under its Sterling Pharma Solutions partnership. Q2 net loss widened to $2.7 million, or ($0.82) per share, from $1.6 million, with R&D expenses rising to $1.7 million on higher trial and manufacturing costs. Cash stood at $5.1 million on June 30, 2025, plus $1.4 million raised July 1, funding operations into Q1 2026.
Via Investor Brand Network · August 14, 2025
InvestorNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted last week in a report from Alliance Global Partners (“AGP”), which maintained its Buy rating for Soligenix and raised SNGX’s price target to $10 per share. According to the report, the increase was based on the increasing valuation of HyBryte(TM) for the treatment of early-stage cutaneous T cell lymphoma (“CTCL”) and new estimated valuation for Soligenix’s SGX945, a treatment for Behçet’s disease.
Via Investor Brand Network · August 11, 2025
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation
Soligenix (NASDAQ: SNGX) today announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators.” The article underscores the growing healthcare challenges of rare diseases among aging Americans and the urgent need for effective therapies. Soligenix is spotlighted for its HyBryte(TM) platform, a novel treatment for cutaneous T-cell lymphoma (CTCL), a rare skin cancer primarily affecting older adults. With U.S.-based manufacturing now established for HyBryte’s active ingredient, Soligenix demonstrates a commitment to domestic innovation and support for underserved patient populations.
Via Investor Brand Network · August 7, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
By Soligenix, Inc. · Via GlobeNewswire · August 7, 2025
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage : As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is working to advance this mission with its HyBryte(“TM”) platform, a new therapy for cutaneous T-cell lymphoma (“CTCL”), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and…
Via Investor Brand Network · August 6, 2025
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END
Via FinancialNewsMedia · August 6, 2025
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older adults—represents a promising solution. With successful domestic manufacturing of HyBryte’s active ingredient, the company advances its mission to serve this underserved demographic with innovative, U.S.-based therapies.
Via Investor Brand Network · August 5, 2025
Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes
On average, diabetics tend to suffer from depression at higher rates than is seen in the general population. A new study conducted by a team at the German Diabetes Center and other institutions in Germany has found that the markers of chronic inflammation influence how successful the treatments provided for depression will be for patients living with diabetes.
Via Investor Brand Network · August 5, 2025